HPV Agonist Epitopes Targeting E6 and E7 Oncoproteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic HPV vaccines are not approved by the FDA, and there is a need for a vaccine that enhances the lysis of human tumor cells associated with HPV infections, such as cervical, anal, and head and neck cancers.
Innovation Solution
Development of peptides and polypeptides comprising specific amino acid sequences (e.g., SEQ ID NO: 1, 2, and 3) derived from HPV-16 E6 and E7 proteins, which can be used to inhibit HPV infection, enhance immune response, treat HPV-associated cancers, and prevent metastatic progression by administering these compositions to subjects, either directly or through lymphocytes and dendritic cells stimulated ex vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a therapeutic HPV vaccine is developed to enhance lysis of human tumor cells, then the immune response against HPV-associated cancers is improved, but the complexity of vaccine development and approval increases
Solution Approach 1:
The vaccine design segments the HPV oncoproteins E6 and E7 into specific epitopic peptides (e.g., E6-A1, E6-A2, E6-A3, E7-A1, E7-A2, E7-A3) that can be individually synthesized and tested. This segmentation allows for targeted immune response against specific tumor-associated antigens without requiring the entire protein structure, thereby enhancing therapeutic efficacy while managing development complexity.
Solution Approach 2:
The invention modifies the amino acid sequences of the E6 and E7 proteins to create optimized epitopic peptides with enhanced immunogenicity. Specific parameter changes include altering peptide length, amino acid composition, and structural conformation to improve T-cell recognition and immune response while maintaining specificity for HPV-associated cancer cells.
2Manufacturing precision
If specific amino acid sequences from HPV-16 E6 and E7 proteins are used to target oncogenic proteins, then the precision of cancer treatment is improved, but the difficulty of identifying effective epitopes increases
Solution Approach 1:
The invention performs preliminary identification and characterization of multiple candidate epitopic peptides from HPV-16 E6 and E7 proteins before clinical application. Through in silico modeling, in vitro binding assays, and immunogenicity testing, effective epitopes are pre-selected and validated, reducing the difficulty of identifying therapeutic candidates during later development stages.
Solution Approach 2:
The invention creates simplified copies or representations of the complex HPV oncoproteins by synthesizing specific peptide sequences that replicate the immunogenic properties of the original proteins. These peptide copies (e.g., KLPQLCTEV for E6-A1, QLYNKPLCDV for E6-A3) are easier to manufacture, store, and administer while maintaining therapeutic efficacy.
Data Source
AI summary
The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.